Pharmafile Logo

Carol Stiff

- PMLiVE

New Omicron subvariant appears more transmissible but no more severe than original Omicron strain

The new subvariant is already emerging as a dominant strain in Denmark, the Philippines, Nepal, Qatar and India

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Moderna begins phase 2 trial of Omicron-specific booster

The study will include two groups, with approximately 300 people in each group

Expanding Access to High-Quality Healthcare

Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its...

Impetus Digital

- PMLiVE

Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine

The clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster

- PMLiVE

FDA restricts use of certain antibody treatments for COVID-19

The restrictions reflect recent data that shows these antibodies are not effective against the Omicron variant

- PMLiVE

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

The FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression

- PMLiVE

PM announces plans to lift England’s COVID-19 restrictions

Following the announcement, England is set to remove its ‘Plan B’ COVID-19 restrictions over the next week

Developing Innovative Digital Strategies to Engage Patients

Caitlin Wagner, Associate Marketing Director at Pharming, shares her expertise on innovative patient engagement strategies, including the roles of mobile apps and social media, the impact of the COVID-19 pandemic...

Impetus Digital

- PMLiVE

BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System

Following a successful development and testing programme, the computational system is able to predict high-risk variants of SARS-CoV-2

The New Normal: Upcoming Trends in Clinical Trials

Samuel Searcy, Founder & CEO of CliniStart, shares his expert insights into trends, current gaps, and future predictions for clinical trials. Among many other things, we also dive into his...

Impetus Digital

- PMLiVE

AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants

New data from continued testing has shown that a third booster of Vaxzevria supports an increased antibody response against SARS-CoV-2 variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links